FDA Grants Breakthrough Therapy Designation To Lenvatinib For The Potential Treatment Of Metastatic Renal Cell Carcinoma
Eisai Inc. announced today the U.S. Food and Drug Administration (FDA) granted lenvatinib, the company's multiple receptor tyrosine kinase inhibitor, Breakthrough Therapy designation for the investigational use in patients with advanced or metastatic renal cell carcinoma (RCC) who were previously treated with a vascular endothelial growth factor (VEGF)-targeted therapy.07/29/2015
Source: Kidney Cancer Association - Category: Cancer & Oncology Source Type: news
More News: Cancer | Cancer & Oncology | Carcinoma | Food and Drug Administration (FDA) | Grants | Kidney Cancer | Renal Cell Carcinoma | Urology & Nephrology